Ibrutinib treatment of CLL: the cancer fights back

Ryan M Young; Louis M Staudt

doi:10.1016/j.ccr.2014.06.023

Ibrutinib treatment of CLL: the cancer fights back

Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.

Authors

Ryan M Young¹, Louis M Staudt²

Affiliations

¹ Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
² Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: lstaudt@mail.nih.gov.

Abstract

Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK). Studies published in the New England Journal of Medicine report that patients with chronic lymphocytic leukemia (CLL) have durable responses to ibrutinib, but they also describe the advent of bypass mutations that result in ibrutinib resistance and progressive disease.

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Antineoplastic Agents / therapeutic use*
Disease Progression
Drug Resistance, Neoplasm
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Molecular Targeted Therapy
Mutation
Piperidines
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human
Adenine

Grants and funding

ZIA BC011010-06/Intramural NIH HHS/United States